PCM
RLMD icon

Prelude Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Prelude Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,642
Closed -$46.9K – 1300
2023
Q3 		$46.9K Sell
15,642
-2,958
-16% -$8.79K ﹤0.01% 1050
2023
Q2 		$45.8K Buy
18,600
+1,900
+11% +$5.25K ﹤0.01% 977
2023
Q1 		$37.7K Buy
+16,700
New +$57.6K ﹤0.01% 1021
2020
Q1 		– Sell
-121
Closed -$5K – 1941
2019
Q4 		$5K Buy
+121
New +$3.68K ﹤0.01% 1778

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prelude Capital Management's RLMD Position: Q4 2023 in Review

Prelude Capital Management sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 15,642 shares — an estimated $46.9K sold.

Prelude Capital Management first reported a position in RLMD in Q4 2019 and held it in 4 quarters. The position peaked at $46.9K in Q3 2023. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Prelude Capital Management reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 15,642 Relmada Therapeutics shares in Q4 2023, an estimated $46.9K.
  • Prelude Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 4 quarters.
  • Prelude Capital Management's Relmada Therapeutics position peaked at $46.9K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.